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Objective. The objective of this study is to ascertain whether omission of lymphadenectomy could be possible when uterine
corpus cancer is considered low-risk based on intraoperative pathologic indicators. Patient and Methods. Between 1998 and
2007, a total of 83 patients with low risk corpus cancer (endometrioid type, grade 1 or 2, myometrial invasion 50%, and no
intraoperative evidence of macroscopic extrauterine spread, including pelvic and paraaortic lymph node swelling and adnexal
metastasis) underwent the total abdominal hysterectomy and bilateral salpingo-oophorectomy without lymphadenectomy. A
retrospective review of the medical records was performed, and the disease-free survival (DFS), overall survival (OS), peri- and
postoperative morbidities and complications were evaluated. Results. The 5-year DFS rates and the 5-year OS rates were 97.6% and
98.8%, respectively. No patient presented postoperative leg lymphedema and deep venous thrombosis. Conclusion. Omission of
lymphadenectomy did not worsen the DFS or OS. The present ﬁndings suggest that systemic lymphadenectomy could be omitted
in low-risk endometrial carcinoma.
1.Introduction
Endometrial cancer is the most frequently occurring gyne-
cologic malignancy. It accounts for 6% of all cancers in
women, and causes approximately 42,000 deaths annually,
which represents 3% of cancer deaths in women in the
United States [1]. Most of the cancers are detected at an
early stage by common symptom such as postmenopausal
bleeding, with the tumor conﬁned to the uterine corpus, so
the prognosis is generally favorable and surgery alone may
result in a cure. The ﬁve-year survival rate for stage IA or IB
disease is reported to be over 90% [2, 3].
The International Federation of Gynecology and Obstet-
rics (FIGO) recommended in 1988 that adequate surgical
staging requires a total abdominal hysterectomy, bilateral
salpingo-oophorectomy (TAH-BSO) including pelvic and
paraaortic lymphadenectomy [4], and according to this
recommendation, some surgeons believe that lymphadenec-
tomy should be performed in all cases to enable the accurate
staging and to assess the necessity for postoperative treat-
ment. However, there are some risks to lymphadenectomy
such as postoperative deep vein thrombosis or leg lym-
phedemawhichmayimpairthepatients’qualityoflife.Mari-
ani et al. reported that low-risk corpus cancer (endometrioid
type, grade 1 or 2 tumor, myometrial invasion 50%,
and no intraoperative evidence of macroscopic extrauterine
spread) could be treated optimally with hysterectomy only
[5]. We retrospectively reviewed the cases of low-risk corpus
cancer, which were treated in our hospital, and clariﬁed
that lymphadenectomy did not provide a signiﬁcant survival
advantage,andincreasedperi-andpostoperativemorbidities
andcomplications[6].Accordingtotheseresults,since1998,
lymphadenectomy have been omitted in low-risk corpus
cancer in our hospital. We retrospectively reviewed these
cases and evaluated whether omission of lymphadenectomy
for low-risk corpus cancer worsen the disease-free survival
(DFS), overall survival (OS), and avoid peri- and postopera-
tive morbidities and complications.
2. Patients andMethods
Eighty-three patients (median age: 55 years, range: 27–
80 years) with endometrioid corpus cancer, grade 1 or 2
tumor, myometrial invasion 50%, and no intraoperative
evidence of macroscopic extrauterine spread, including
pelvic and paraaortic lymph node swelling and adnexal2 Obstetrics and Gynecology International
Table 1: Patients characteristics (n = 83).
Age (years)
Mean ± SD 56.2 ±12.1
Median 55
Range 27–80
WHO∗ performance status, no.
05 9
11 4
>20
FIGO∗∗ surgical stage, no.
Ia 32
Ib 43
Ic 3
IIIa 5
Adjuvant chemotherapy, no.
None 74
Paclitaxel/carboplatin§ 9
Follow up interval (months)
Median (range) 72 (4–120)
WHO∗: World Health Organization, FIGO∗∗: International Federation of
Gynecology and Obstetrics Paclitaxel/carboplatin §: Paclitaxel (180mg/m2)
and carboplatin (area under the curve; AUC 5).
metastasis, were treated surgically at the Department of
Obstetrics and Gynecology of University of Toyama during
the period 1998 to 2007. In all these cases, we preoperatively
assessed whether endometrial cancer is considered low-
risk (myometrial invasion 50%, no lymphadenopathy and
grade 1 or 2 endometrioid corpus cancer), using computed
tomography, magnetic resonance imaging, glucose analog
[18F]-ﬂuoro-2-deoxy-D-glucose positron emission tomog-
raphy and endometrial biopsy.
All patients routinely underwent TAH-BSO without
lymphadenectomy. If the depth of myometrial invasion was
determined to be >50%, or the tumor was classiﬁed grade 3
endometrioid corpus cancer based on intraoperative frozen-
section analysis, we performed systemic lymphadenectomy.
In cases which lymph nodes were enlarged or suspi-
cious, we performed selective lymph node sampling. Non-
endometrioidhistologictypessuchasserousorclearcelltype
and grade 3 tumor were excluded from this study, since all of
these patients underwent TAH-BSO with lymphadenectomy
because of their poor prognosis. After operation, patients
were seen every month for one year, and every 3 months
thereafter for 120 months.
We performed a retrospective review of the medical
records, and the disease-free survival (DFS; the interval
between the date of operation and the date of recurrence
of disease), overall survival (OS; the interval between the
date of operation and the date of death), and peri-operative
morbidities including operative time, estimated blood loss
during operation, and the percentage of patients requiring
transfusion were evaluated. We also estimated the incidence
of postoperative complications such as leg lymphedema and
Table 2:Characteristicsofthehistopathologicalprognosticfeatures
(n = 83).
H i s t o l o g i c a lg r a d e ,n o .
G1 72
G2 10
G3 1
Depth of myometrial invasion >50%, no.
None 32
50% 48
>50% 3
Lymphvascular space involvement, no.
Yes 5
No 78
Peritoneal cytology, no.
Positive 5
Negative 78
Tumor diameter, no.
<20mm 44
20mm 39
deep vein thrombosis diagnosed by nuclear venography. The
DFS and OS curves were estimated using the Kaplan-Meier
method.
3. Results
Patients’ characteristics are shown in Table 1. The median
age of the patients was 55 years (range, 27–80 years). The
distribution of FIGO surgical stage was Ia, 32; Ib, 43; Ic, 3,
IIIa, 5; and 8 cases (9.6%) were upstaged postoperatively.
Pelvic lymph node sampling was performed in 7 cases, which
werediagnosedwithnegativenodes.Adjuvantchemotherapy
consisting of intravenous paclitaxel (180mg/m2)a n dc a r b o -
platin (AUC 5) was administered to 9 upstaged, upgraded or
lymphvascular space involvement-positive cases. No patients
received adjuvant radiotherapy. The median followup period
was 72 months (range, 4–120 months).
Characteristics of the histopathological prognostic fea-
tures are shown in Table 2. The distribution of histological
grade was grade 1, 72; grade 2, 10; grade 3, 1; and 1 case
(1.2%) was upgraded postoperatively. Depth of myometrial
invasion was >50% in 3 cases. Lymphvascular space involve-
ment was observed in 5 cases. Positive peritoneal cytology
was observed in 5 case. Thirty-nine patients had tumor
diameter 20mm.
T h eD F Sc u r v ea n dt h eO Sc u r v ea r es h o w ni nFigure 1
(left; the DFS curve, right: the OS curve). The 5-year DFS
rates and the 5-year OS rates were 97.6% and 98.8%,
respectively.
Peri- and postoperative morbidities and complications
are shown in Table 3. The mean operative time was 129 ± 28
minutes. The mean estimated blood loss during operation
was 244±192mL, and the percentage of transfusion require-
ment was 2.4%. No patient presented with postoperative leg
lymphedema or postoperative deep venous thrombosis.Obstetrics and Gynecology International 3
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Figure 1: Survival curves.
Table 3: Peri- and postoperative morbidities and complications.
Peri- and postoperative factors
Operative time∗ (min) 129 ± 28
Estimated blood loss during
operation∗ (mL)
244 ±192
Transfusion requirement, no. 2
Postoperative leg lymphedema
(grade 2, NCI-CTC ver. 2.0),
no.
0
Postoperative deep vein
thrombosis, no.
0
∗The values were expressed as the mean ± SD.
4. Discussion
In 1988, FIGO recommended a systemic surgical staging
systemforcorpuscancer[4].Accordingtothisrecommenda-
tion, many gynecologic oncologists believe that systemic sur-
gical staging including pelvic and paraaortic lymphadenec-
tomy is the best surgical treatment to achieve a good
prognosis for corpus cancer patients. However, controversy
has persisited regarding the need for lymphadenectomy [5–
9]. There is no doubt that surgical staging is more accurate
than clinical staging, and there are some cases which need
upstaging to higher stages after surgery [10–12]. However,
Morrow et al. reported that only 18 (2%) out of 895 patients
had positive pelvic lymph nodes in the abscence of operative
ﬁndings by palpation [13]. Creasman et al. demonstrated
by multivariate analysis that in clinical stage I patients with
grade 1 or 2 and depth of invasion within the middle 1/3,
theincidenceofpelviclymphnode metastaseswasonly3.6%
[7]. Chi et al. showed that the incidence of pelvic lymph
node metastases in low-risk corpus cancer (grade; 1, 2, and
depth of myometrial invasion; none or inner half) was 5.3%
(14/162) [14]. As for grading, Ben-Shachar et al. reported
that only 6 (3.3%) of 181 patients preoperatively diagnosed
with grade 1 disease by biopsy were upgraded after surgical
staging [15]. In this study, 8 of the 83 were upstaged or
upgraded after surgical staging.
Regarding the role of lymphadenectomy on prognosis,
Mariani et al. reported that patients who had grade 1 or 2
endometrioid corpus cancer with greatest surface dimension
2cm, myometrial invasion 50%, and no intraoperative
evidence of macroscopic disease could be treated optimally
with hysterectomy only with favorable prognosis of up to
97% for 5-year overall cancer-related survival [5]. Further-
more, Trimble et al. demonstrated that the 5-year relative
survival for 6,363 women with stage I endometrial cancer
who did not undergo lymph node sampling was 98%, com-
paredto96%for2,831womenwhodidundergolymphnode
sampling at the time of hysterectomy with a no signiﬁcant
diﬀerence, and concluded that lymph node sampling did
not appear to convey survival beneﬁt, especially in stage I,
grade 1 or 2, endometrial cancer by subgroup analysis [9]
Recently, Kitchener et al. compared the standard surgery
group (hysterectomy and bilateral salpingo-oophorectomy,
peritoneal washings, and palpation of para-aortic nodes;
n = 704) and the lymphadenectomy group (standard
surgery plus lymphadenectomy; n = 704) for histolgically
proven endometrial carcinoma thought preoperatively to
be conﬁned to the corpus in a randomised study and
showed that the hazard ratio (HR) for overall survival was
1.04 (0.74–1.45; P = .8 3 )a n dH Rf o rr e c u r r e n c e - f r e e
survival was 1.25 (0.93–1.66; P = .14), both in favour of
standard surgery, and concluded that there was no evidence
of beneﬁt in terms of overall or recurrence-free survival
for pelvic lymphadenectomy with early endometrial cancer,
and that pelvic lymphadenectomy cannot be recommended
as routine procedure for therapeutic purposes outside of
clinical trials [16]. Panici et al. also, compared the pelvic
systematic lymphadenectomy arm (n = 264) and no
lymphadenectomy arm (n = 250) for preoperative FIGO
stage I endometrial carcinoma and showed that the 5-year4 Obstetrics and Gynecology International
disease-free and overall survival rates were similar between
the two arms (81.0% and 85.9% in the lymphadenectomy
armand81.7%and90.0%intheno-lymphadenectomyarm)
[17]. In summary, omission of complete lymphadenectomy
is possible in selected cases in which the risk of lymph node
spread is low, in other words, low-risk cancer. The deﬁnition
of low-risk in corpus cancer at the operation is controversial;
however, taking many reports into consideration, we regard
grade 1 or 2 endometrioid corpus cancer with myometrial
invasion 50%, and no intraoperative evidence of macro-
scopic disease as low-risk [5–9, 18, 19].
There were 8 upstaged patients on ﬁnal pathology who
were thought low-risk on pre- and intraoperative evaluation.
This result means that there is some limitation about the
accuracyofpre-andintraoperativeevaluationofmyometrial
invasion and tumor grade. Montalto et al. reported that
accuracy of intraoperative frozen section diagnosis for grade
of diﬀerentiation and depth of myometrial invasion were
84.3% and 94.3%, respectively [20]. For those upgraded,
upstaged or lymphvascular space involvement-positive cases,
as well as, non-endometrioid adenocarcinoma such as uter-
ine papillary serous carcinoma, which is clinically aggressive,
adjuvanttreatmentshouldbeconsidered.Recently,paclitaxel
has been shown to be eﬀective against advanced and recur-
rent endometrial carcinoma [21–25]. Therefore, we added
systemic chemotherapy (a paclitaxel/carboplatin regimen) as
adjuvanttreatmentforupgraded,upstagedorlymphvascular
space involvement-positive cases.
Several investigators have reported that addition of
lymphadenectomy to TAH-BSO increases the risk of com-
plications and morbidities such as more blood transfusions,
longer hospital stay, lymphedema, gastrointestinal injury,
and the development of lymphocysts [26–28]. Framarino
et al. reported that addition of pelvic and paraaortic
lymphadenectomytoTAH-BSOsigniﬁcantlyincreasedmean
operative time, mean estimated blood loss, and postoper-
ative hospital stay compared to TAH-BSO alone, without
improving mortality [28]. Panici et al. showed that postoper-
ative complications occurred statistically signiﬁcantly more
frequently in patients who had received pelvic systematic
lymphadenectomy (81/264; 30.7% in the lymphadenectomy
arm and 34/250; 13.6% in the no-lymphadenectomy arm,
P = .001) [17]. Also in our previous study, mean operative
time, mean estimated blood loss during operation, the
percentage of cases requiring transfusion, and the incidence
of leg lymphedema were signiﬁcantly (P<. 001) increased by
addition of lymphadenectomy [6]. In any case, postoperative
complications are expected from the surgical procedure
itself, and addition of lymphadenctomy may increase the
incidence of those complication, especially in corpus cancer
patients, many of whom have morbidities such as hyperten-
sion, obesity, diabetes mellitus, and older age [29, 30].
5. Conclusion
A clinically important goal of surgical treatment including
lymphadenectomy for low-risk corpus cancer patients is not
only to determine the extent of disease and an accurate
prognosis, but also to obtain a favorable prognosis without
causing any complications. Our data demonstrate that
omission of lymphadenectomy did not worsen the disease-
free or overall survival, and as a result, peri- and post-
operative morbidities and complications could be avoided.
Thepresentﬁndingssuggestthatsystemiclymphadenectomy
could be omitted in low-risk endometrial carcinoma. These
results should be conﬁrmed in future prospective large-scale
randomized clinical trials.
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